AbbVie
ABBV
1,634 hedge funds and large institutions have $69.9B invested in AbbVie in 2016 Q2 according to their latest regulatory filings, with 97 funds opening new positions, 621 increasing their positions, 698 reducing their positions, and 86 closing their positions.
16% more funds holding in top 10
Funds holding in top 10: 81 → 94 (+13)
13% more first-time investments, than exits
New positions opened: 97 | Existing positions closed: 86
12% more capital invested
Capital invested by funds: $62.5B → $69.9B (+$7.32B)
0% less funds holding
Funds holding: 1,638 → 1,634 (-4)
2.72% less ownership
Funds ownership: 69.94% → 67.22% (-2.7%)
11% less repeat investments, than reductions
Existing positions increased: 621 | Existing positions reduced: 698
26% less call options, than puts
Call options by funds: $1.17B | Put options by funds: $1.58B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$4.67B |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$217M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$116M |
| 4 |
SUT
SC US (TTGP)
Menlo Park,
California
|
+$87.5M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$83.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal London Asset Management
United Kingdom
|
-$1.36B |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$699M |
| 3 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$233M |
| 4 |
AIM
abrdn Investment Management
Edinburgh,
United Kingdom
|
-$210M |
| 5 |
VOYA Investment Management
Atlanta,
Georgia
|
-$196M |
ABBV Hedge Fund Activity: Q2 2016 in Review
1,634 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q2 2016, worth a combined $69.9B — up 12% from $62.5B a quarter earlier.
Buyers outnumbered sellers: 97 funds opened new ABBV positions and 86 closed out — a net gain of 11 holders — while 621 added to existing stakes and 698 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $4.67B. The largest seller was Royal London Asset Management, cutting an estimated $1.36B.
- 1,634 institutional investors held AbbVie (ABBV) as of Q2 2016, down from 1,638 in Q1 2016.
- Funds reported $69.9B of AbbVie stock for Q2 2016, up 12% quarter-over-quarter.
- 97 funds opened new AbbVie positions in Q2 2016 and 86 closed out, a net change of +11 holders.
- The largest AbbVie buyer in Q2 2016 was Capital Research Global Investors, an estimated $4.67B added.
- The largest AbbVie seller in Q2 2016 was Royal London Asset Management, an estimated $1.36B sold.
Based on aggregated 13F filings for Q2 2016.